Direct comparison
Expedited vs. Full Board IRB Review
IRB expedited vs. full board review compared: 45 CFR 46.110 eligibility, who can disapprove, timelines, and what triggers a mid-study switch.
Written and maintained by CASRAI Editorial Board
Last updated
Ask CASRAI · included with Regulatory Radar
Ask about Expedited vs. Full Board IRB Review
Ask CASRAI answers research-administration questions and cites the passages behind every claim — and says so when the corpus does not cover something, instead of guessing. It comes with a Regulatory Radar subscription at $29 a month, alongside the daily digest of regulatory changes and the dashboard of what changed.
150 questions a day, on this site, over the API, or inside your own tools through the CASRAI MCP server.
Everything CASRAI publishes — this page, the dictionary, the guides and the news — stays free to read, with no account and no card.
How do Expedited Review, Full Board Review compare side by side?
The table below compares Expedited Review, Full Board Review across 7 procurement-relevant dimensions, from who reviews through can change mid-study.
Side-by-side comparison
| Dimension | Expedited Review | Full Board Review |
|---|---|---|
| Who reviews | IRB Chair, or one or more Chair-designated experienced reviewers | The full convened IRB, quorum present (majority of members, including at least one non-scientist) |
| Risk threshold | No more than minimal risk | Greater than minimal risk, OR minimal risk that does not fit an expedited category |
| Eligibility basis | Must satisfy BOTH the minimal-risk standard AND fit one of OHRP's enumerated expedited categories (45 CFR 46.110 / 21 CFR 56.110) | Default pathway for any non-exempt, non-expedited-eligible human subjects research (45 CFR 46.108) |
| Can it disapprove a study? | No -- disapproval is reserved for the convened board | Yes -- the only pathway that can disapprove |
| Typical timeline | Days to roughly 1-2 weeks; not tied to a meeting date | Weeks to a month or more, tied to the IRB’s scheduled (commonly monthly) meeting calendar and submission deadlines |
| Continuing review | Often exempt from the continuing-review requirement entirely under 45 CFR 46.109(f) (2018 Common Rule revisions) | Required at least annually per 45 CFR 46.109(e) for as long as the study needs convened-board review; FDA-regulated research (21 CFR 56.109(f)) has no equivalent exception |
| Can change mid-study | Can be elevated to full board by a risk-increasing amendment, new safety information, or a reviewer eligibility determination | Can move to expedited only in narrow, defined circumstances (e.g., certain minor changes to previously approved research) |
Common questions
Common questions about Expedited Review vs Full Board Review
Can one reviewer disapprove a study under expedited review?
+
No. An expedited reviewer can approve or require modifications, but disapproval is reserved exclusively for a convened meeting of the full IRB under 45 CFR 46.108(b).
Who decides whether a study qualifies for expedited review?
+
IRB staff typically make an initial screening determination, which the IRB Chair or a designated experienced reviewer confirms when the review begins, checking both the minimal-risk standard and category fit.
Is expedited review the same as exempt research?
+
No. Exempt research is excused from most IRB oversight requirements under specific Common Rule categories; expedited research still receives a full substantive IRB review, just by one or a few reviewers instead of the convened board.
Does expedited review mean less scrutiny?
+
Not in principle -- the substantive approval standard is the same. What differs is who reviews it and whether disapproval is possible at that level.
